# Synergistic Enteral Regimen for Treatment of the Gangliosidoses

> **NCT02030015** · PHASE4 · TERMINATED · sponsor: **University of Minnesota** · enrollment: 16 (actual)

## Conditions studied

- GM1 Gangliosidoses
- GM2 Gangliosidoses
- Tay-Sachs Disease
- Sandhoff Disease

## Interventions

- **DRUG:** miglustat
- **OTHER:** Ketogenic Diet

## Key facts

- **NCT ID:** NCT02030015
- **Lead sponsor:** University of Minnesota
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-12-22
- **Primary completion:** 2019-07-31
- **Final completion:** 2019-07-31
- **Target enrollment:** 16 (ACTUAL)
- **Why stopped:** Efficacy
- **Last updated:** 2021-04-14

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02030015

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02030015, "Synergistic Enteral Regimen for Treatment of the Gangliosidoses". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02030015. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*